From Yahoo Finance: 2025-05-10 11:00:00

BlackRock reports international equities outperform US equities by 11% in 2025, with value stocks gaining favor over growth stocks. Active management strategies are beneficial in fluctuating markets, especially within defensive sectors like healthcare. US large-cap value equities remain positive YTD, with opportunities in defensive sectors amidst new trade policies.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scrutinized as a potential worst blue chip stock to buy, ranking 6th on the list. Despite a 26.2% YTD decline, analyst John Newman maintains a “Buy” rating and a $850 price target due to the company’s diversification of revenue streams and market opportunities. Factor XI program advancements and FDA approvals contribute to its long-term growth prospects.

Baron Funds praises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) as an attractive investment opportunity due to its successful drug developments like Eylea and Dupixent. The company’s robust pipeline, including treatments for severe food allergies and blood clot prevention, indicates potential for future successes and stock upside. The stock is part of Baron Funds’ investment portfolio.

Fiduciary Trust suggests making portfolio adjustments in response to prolonged tariff discussions and changing average tariff rates. Strong capex spending on AI is expected to drive long-term productivity, potentially enhancing bank lending and stock buybacks. AI stocks are highlighted as promising investments, with deeply undervalued options offering higher returns within a shorter timeframe.

Read more: Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Blue Chip Stock to Buy?